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Abstract
Background: The incidence of ischemic stroke in young patients is increasing and associated 
with unfavorable prognosis due to high risk of recurrent cardiovascular events. In many 
young patients the cause of stroke remains unknown, referred to as cryptogenic stroke. 
Neuroimaging frequently suggests a proximal source of embolism in these strokes. We 
developed a comprehensive step-by-step echocardiography protocol for a prospective 
study with centralized reading to characterize preclinical cardiac changes associated with 
cryptogenic stroke.
Methods and study design: SECRETO (Searching for Explanations for Cryptogenic Stroke in 
the Young: Revealing the Etiology, Triggers, and Outcome; NCT01934725) is an ongoing 
multicenter case–control study enrolling patients (target n = 600) aged 18–49 years 
hospitalized due to first-ever ischemic stroke of undetermined etiology and age- and 
sex-matched controls (target n = 600). A comprehensive assessment of cardiovascular 
risk factors and extensive cardiac imaging with transthoracic and transesophageal 
echocardiography, electrocardiography and neurovascular imaging is performed. 
Transthoracic and transesophageal echocardiograms will be centrally read, following an 
extensive protocol particularly emphasizing the characteristics of left atrium, left atrial 
appendage and interatrial septum.
Conclusions: A detailed assessment of both conventional and unconventional vascular risk 
factors and cardiac imaging with transthoracic and transesophageal echocardiography are 
implemented in SECRETO, aiming to establish indirect and direct risk factors and causes for 
cryptogenic stroke and novel pathophysiological brain–heart pathways. This may ultimately 
enable more personalized therapeutic options for these patients.
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Introduction
The incidence of ischemic stroke in young patients is 
increasing globally (1). Stroke at younger ages is associated 
with increased morbidity and mortality, in particular with 
respect to recurrent cardiovascular events (2). Cardiac 
sources of embolism underlie 15–40% of all ischemic 
strokes and include a wide range of cardiac conditions 
(3). However, the cause of stroke in 30–50% of younger 
adults remains unknown, also termed as cryptogenic 
stroke (4, 5, 6). In many young patients with cryptogenic 
stroke, neuroimaging pattern suggests a proximal source 
of embolism. Notably, the risk of recurrent stroke in these 
patients was comparable to those with established major 
source of cardioembolism (7).
The etiology of cardioembolic sources of ischemic 
stroke may be classified as major, minor or uncertain (3, 
8). Major cardioembolic causes include atrial fibrillation 
or flutter, recent or previous myocardial infarction with 
apical akinesia, left ventricular (LV) aneurysm, dilated 
cardiomyopathy, reduced LV ejection fraction (<35%), 
LV or left atrial appendage (LAA) thrombus, rheumatic 
and prosthetic heart valve disease, infective endocarditis, 
intracardiac tumors, congenital heart diseases, Takotsubo-
cardiomyopathy and atherosclerosis in the ascending 
aorta and aortic arch, while minor or uncertain causes 
are as patent foramen ovale (PFO), mitral valve prolapse, 
mitral annular calcification, degenerative aortic stenosis, 
atrial septum aneurysm, spontaneous contrast on the 
echocardiogram, aortic aneurysm, false tendon in the LV, 
moderate to severe left atrium (LA) enlargement and LV 
hypertrophy (3, 4, 5, 6, 7, 8).
In particular, PFO has gained much attention recently 
due to positive results from trials comparing transcatheter 
PFO closure with medical therapy in the secondary stroke 
prevention (9). Currently, stroke in a patient with PFO is 
classified as cryptogenic if no other cause is identifiable 
in stroke classification systems. An European Expert Panel 
recently proposed that when PFO is believed likely to 
be implicated in a cryptogenic stroke, the event should 
be classified as PFO-related stroke (10). The panel also 
stressed that research should continue to verify additional 
risk factors and identify new high-risk phenotypes for 
PFO-related stroke, comprising an array of clinical, 
biochemical and cardiovascular imaging characteristics. 
In view of these considerations, an extensive assessment of 
cardiovascular risk factors and cardiac imaging is required 
to elucidate direct and indirect causes of cryptogenic stroke 
and subsequently offer these patients a more personalized 
therapeutic management. In the present paper, we present 
a step-by-step transthoracic (TTE) and transesophageal 
echocardiography (TEE) performance protocol for the 
multicenter international case–control study, Searching 
for Explanations for Cryptogenic Stroke in the Young: 
Revealing the Etiology, Triggers, and Outcome (SECRETO; 
NCT01934725) (11).
Study design
SECRETO is an international multicenter prospective 
case–control study of young adults (aged 18–49  years) 
presenting with a documented first-ever ischemic stroke 
of undetermined etiology. Patients are included after 
standardized diagnostic procedures: brain MRI, imaging 
of intracranial and extracranial vessels, TTE and TEE, ECG 
and screening for coagulopathies. Stroke-free healthy 
control participants are recruited and matched with index 
patients by age (within 5 years), sex and ethnicity in a 1:1 
fashion, as per the STROBE (STrengthening the Reporting 
of OBservational studies in Epidemiology) guidelines 
at each study site. As the incidence of ischemic stroke 
is approximately 10/100,000 per year in this age group 
(12), an international consortium has been established 
to recruit a sufficient number of patients in a reasonable 
time. Recruitment of subjects began in 2013 and is 
expected to be completed by the end of 2020 aiming to 
enroll a total of 600 patients and 600 control subjects. 
As of March 2019, 17 European centers are participating 
in SECRETO. The SECRETO study was approved by local 
ethical committtees in all recruiting centers. Written 
informed consent was obtained and will be obtained from 
all study subjects prior to study enrollment.
Objectives
The principal aim of SECRETO is to document new risk 
factors and pathogenic pathways leading to currently 
cryptogenic stroke in the young. Specifically regarding the 
investigations on proximal sources of embolism, we aimed to 
(1) develop a standardized echocardiography performance 
protocol exceeding state-of-the-art; (2) to compare cardiac 
structural and functional findings in a case-control study 
to establish novel cardiac sources for embolism and (3) to 
use these data to explore cardiac structural and functional 
characteristics associated with recurrent thromboembolic 
events in a long-term follow-up. The cardiac imaging data 
can be further cross-linked with clinical risk factor data, 
neuroimaging findings, blood markers of thrombosis 
and hemostasis and genetic profiles. Finally, systems and 
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precision medicine approaches can be applied to identify 
clusters of clinical and cardio-anatomical, and biological 
characteristics to construct more holistic explanatory 
models for cryptogenic stroke.
Measures and clinical data at baseline
At baseline during hospitalization for the index stroke and 
at follow-up visit anthropometrics (height, weight, waist 
and hip circumference), blood pressure and heart rate are 
measured. Clinical data including an extensive review 
of neurological symptoms at presentation, diagnostic 
work-up, treatments, conventional and unconventional 
stroke risk factor information are collected using structured 
questionnaires. Brain and neurovascular imaging are 
subject to blinded central reading. A standard 12-lead 
ECG is obtained on admission, and after the acute phase.
Echocardiography
A step-by-step performance protocol was developed for TTE 
and TEE to allow their accurate and blinded central reading 
(SS) at Echo Core Lab in University of Bergen, Norway.
The protocol is based upon standard recommendations 
for the use of TTE and TEE (3). Particular emphasis will 
be placed on the measures of left and right atrium, atrial 
septum, LAA, the anatomical shape and size of PFO and its 
relation with aortic root and other adjacent structures, as 
well as interatrial and intrapulmonary (delayed) shunts. 
TTE may be the only cardiac imaging in cases with very 
severe stroke, receptive aphasia, or swallowing difficulties.
Transthoracic echocardiography
Each study is labeled with a study ID and date. Age, 
height and weight are entered to calculate body surface 
area. A sweep speed of 100 mm/s for all M-mode and 
Doppler recording are used. A loop of three RR intervals 
of all images in patients with sinus rhythm and five RR 
intervals in patients with atrial fibrillation is recorded. 
The order and modalities used to obtain the required 
TTE images are presented in Figs  1 and 2. Quantitative 
assessment of right ventricle, LV dimension and volumes 
are performed according to current international 
guidelines on quantitative echocardiography (13). LV 
systolic function is assessed by biplane Simpson’s ejection 
fraction (13). Diastolic function is assessed according to 
current European guidelines (14).
Following TTE, supine brachial blood pressure is 
measured on the left arm (phase 1 and 5 Korotkoff 
sound) using an appropriately sized cuff and a regularly 
calibrated aneroid blood pressure sphygmomanometer. 
The measurements are recorded and provided along with 
the echocardiography images.
Transesophageal echocardiography
Prior to TEE, patients should have been fasting for at least 
6 h. Benzodiazepines (diazepam or midazolam) are the 
Box 1: Variables assessed by transesophageal 
echocardiography in SECRETO.
Aortic annulus diameter (cm) 
Aortic sinus diameter (cm)
Sinotubular junction diameter (cm)
Ascending aortic diameter (cm)
Aortic arch atheromatosis (plaque thickness ≥4 mm)
Descending aortic wall thickness (mm)
Aortic valve cusps (numbers and morphology)
Aortic valve calcification
Tumors
Vegetation/infective endocarditis, peri-valvular edema/
inflammation
Atrial septal defect
Patent foramen ovale (PFO)
Spontaneous left-to-right shunt assessed by color Doppler 
imaging
Shift of shunt direction after Valsalva maneuver
PFO diameter (mm)
PFO tunnel length (mm)
Assessment of delayed intrapulmonary shunt with bubble 
study
Atrial septal aneurysm (ASA) ≥10 mm
Hypertrophy of interatrial septum (lipomatous 
hypertrophy)
Prominent Eustachian valvea
Left atrial thrombus/mass
Left atrial appendage (LAA) thrombus
Slow left atrial appendage flow velocity (peak velocity 
≤30 cm/s)
Ridge between left upper pulmonary vein and LAA and 
pectinate muscle
Spontaneous echo contrast
Mitral annular calcification and leaflet thickness 
Etiology of mitral regurgitation (functional, degenerative, 
mixed)
Mitral regurgitation grade (I-IV):
  Quantitative assessment with PISA, vena contracta, 
regurgitant volume, EROA
Aortic valve calcification: mild moderate severe
Aortic regurgitation: mild moderate severe
Tricuspid regurgitation: mild moderate severe 
aDefined as valve thickness ≥1 mm with at least 10 mm protrusion 
within the right atrium as measured from the border of inferior 
vena cava.
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common sedative agents used during TEE. The patient 
is examined awake under a conscious sedative state and 
is able to respond to verbal or tactile stimuli. Xylocaine 
spray is used for local pharyngeal anesthesia. Any jaw 
prosthesis or artificial teeth that are not fixed are removed 
before the probe insertion. The patient is placed in the left 
lateral decubitus position during probe insertion. In the 
mid-line of the mouth the probe is slowly advanced to the 
sophagus. In the final study report, any difficulties during 
probe insertion, procedure-related complications as well 
as image quality and heart rhythm are documented. A 
standardized TEE protocol includes adequate visualization 
of all cardiac chambers, with emphasis on both atria, LAA, 
interatrial septum, heart valves and the thoracic aorta (8). 
The overall TEE parameters implemented in the SECRETO 
study are summarized in Box 1 and in Figs 1 and 3. The 
suggested degrees to assess cardiac structures may vary to 
some extent according to the position of the heart in the 
chest in individual patients.
TEE with bubble study with and without 
Valsalva for the diagnosis of PFO
PFO is diagnosed by TEE with color Doppler imaging 
demonstrating spontaneous left-to-right shunt (from high 
pressure chamber to low pressure chamber) or the shift of 
shunt direction to right-to-left during Valsalva maneuver, 
Figure 1
Echocardiography performance protocol showing 
the order of imaging planes and recommended 
TEE transducer angle °.
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confirmed by bubble study when microbubbles particles 
are visualized in the left atrial chamber in any single 
frame during first 3–5 cycles. An intravenous cannula is 
inserted in the right antecubital vein. For bubble studies, 
administration of intravenous agitated saline is used to 
assess atrial septal defects. Prior to the TEE procedure, 
the patients are given (sufficient) instruction to perform 
a successful Valsalva maneuver. The Valsalva maneuver is 
initiated when the contrast is arrived in the right atrium 
and to release on command after a total of 10–15 cardiac 
cycles. The size of PFO may be quantified by the number of 
microbubbles appearing in the LA (3–10 microbubbles as 
small shunt, 11–30 microbubbles as moderate shunt and 
>30 bubbles as a large shunt) (15). ASA is defined according 
to Olivares classification: Type 1R if the bulging is only in 
the right atrium. Type 2L if the bulging is only in the LA. 
Type 3RL if the major excursion bulges to the right atrium 
and the lesser excursion bulges toward the left. Type 4LR if 
the maximal excursion of the ASA is toward the LA with a 
lesser excursion toward the right atrium. Type 5 if the ASA 
movement is bidirectional and equidistant to both atria 
during the cardiorespiratory cycle (16).
Spontaneous echo contrast is identified as a dynamic 
and slowly swirled smoke-like signal. LAA slow flow 
velocity is defined as peak velocity ≤30 cm/s. The LAA is 
carefully inspected for the presence of thrombus using 
multiplane imaging from 0° to 180°. Furthermore, normal 
variants of cardiac structures and artifacts in right atrium 
(lipomatous hypertrophy of atrial septum, pectinate 
muscles, Chiari network, Eustachian valve, catheters 
and pacemaker leads), LA (the ridge between left upper 
pulmonary vein and LAA) and ventricles (trabeculation, 
false chorda, papillary muscle, catheter and pacemaker 
leads, moderate band in the right ventricle), which are 
essentially not related to embolic events, are distinguished 
from cardiac masses (17).
Figure 2
The number and order of imaging planes in conventional 2D, M-mode, tissue, spectral and color Doppler TTE.
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Discussion
The incidence of ischemic stroke in younger patients 
is increasing, and risk factors are changing over 
time. Among the most likely explanations for this 
worrying observation is the increasing prevalence of 
cardiometabolic risk factors, mainly obesity in young 
individuals in populations (18), leading to early 
development of hypertension and diabetes mellitus 
and vascular aging (19). Contemporary neuroimaging 
suggests proximal source of embolism in a large 
proportion of young patients with cryptogenic stroke, 
thus more comprehensive studies, searching for 
underlying causes of ischemic stroke in the heart or the 
proximal aorta are spoken for. The SECRETO multicenter 
study includes a step-by-step echocardiography protocol 
to explore the cardiac structural and functional risk 
factors as novel causal factors in cryptogenic ischemic 
stroke in the young.
PFO is a common finding in the general population 
with a prevalence of approximately 25% and may well 
be an innocent bystander in a patient with cryptogenic 
Figure 3
(A and B) Upper-esophageal 5-chamber view 0° showing aortic valve (B color Doppler), (C) mid-esophageal 4-chamber view 0°, (D) color Doppler across 
the tricuspid and (E) mitral valve, (F and G) mid-esophageal 2-chamber view showing mitral valve, (H) 2-chamber simultaneous X-plane view showing left 
atria appendage (LAA) without thrombus, (I) short-axis view of LAA combined with color Doppler, (J) zoomed image with color Doppler flow in LAA and left 
upper pulmonary vein [LUPV] at 27°, (K) pulsed-wave velocity in LAA, (L) pulse wave velocity in LUPV, (M and N) mid-esophageal image display of atria, 
inter-atrium septum, Chiari network (arrow) and a patent foramen ovale (PFO) tunnel (red lines) at 100°. (O) Mid-esophageal view showing right atrium 
filled with agitated saline bubbles, (P) short-axis view of atria, atrial septum and a cross-sectional view of aortic valve at 40° (also called procedural view), 
(Q) long-axis view showing mitral and aortic valve at 125°, (R) simultaneous x-plane view of aortic valve, (S) color Doppler flow across mitral (left) and 
aortic valve (right), (T) dimensions at aortic annulus (1), aortic root (2), sinotubular junction (3) and ascending aorta (4) in long-axis view 122°, and (U) a 
simultaneous view of descending aorta, cross-sectional (left) and longitudinal view (right) at 180°.
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stroke (10). Stroke in a patient with PFO is classified as 
cryptogenic if no other cause is identifiable, according 
to existing stroke classification systems. Neuroimaging 
pattern and patient characteristics are typically 
unhelpful in the assessment of PFO’s clinical relevance 
(10). Acute evidence of a deep venous thrombosis or 
pulmonary embolism, recent prolonged travel and 
immobilization or Valsalva maneuver preceding the 
ischemic stroke event, are considered to increase the 
probability of paradoxical embolism due to a right-
to-left shunt (17, 20). The differentiation between an 
incidental and a culprit PFO for index stroke will be 
evaluated based on risk calculators such as the risk 
of paradoxical embolism (RoPE) score (21), clinical 
assessment based on a multidisciplinary approach and 
multimodality imaging. Importantly, due to remaining 
uncertainty in the causality of PFO, a European expert 
panel stressed the need to identify new high-risk PFO 
phenotypes and search additional risk factors that would 
help in prediction of PFO-related events (10).
A patient presenting with the previously mentioned 
risk factors for paradoxical embolism may also have 
other factors that increase the risk of thrombosis, such 
as genetic or acquired pro-thrombotic factors. Similarly, 
a sudden rise in pulmonary arterial pressure due to acute 
pulmonary embolism caused by deep venous thrombosis 
in the lower extremities may contribute to the migration 
of the thrombus across the atrial septum to the systemic 
circulation (20). It is, however, of utmost importance 
to study cardiac characteristics also in patients without 
PFO, in particular, because embolic cortical infarct 
patterns are similar in patients with and without 
PFO (10). Moreover, a patient-level meta-analysis of 
randomized trials suggests that also subcortical infarcts, 
traditionally not considered embolic, may indeed have 
an embolic origin (22).
Of note, previous stroke etiology studies have not 
included a structured, comprehensive cardiac evaluation 
strategy or centralized core laboratory analysis of 
echocardiography (17). In SECRETO, it is mandatory 
to (1) minimize inter-operator variability and (2) allow 
standardized central reading of multiple exploratory 
measures. Therefore, we aimed to develop a comprehensive 
step-by-step TEE protocol to characterize potentially 
pathogenic changes associated with cryptogenic stroke. In 
particular, a standardized TEE with thorough evaluation 
of both atria, LAA, interatrial septum aneurysm and defect 
and the anatomical shape and size of PFO is applied. All 
these factors have been linked to PFO-associated strokes 
in retrospective studies (23, 24).
Poor performance of Valsalva may hamper 
identification of PFO. However, we complement 
echocardiography studies with a prior transcranial 
Doppler ultrasound bubble test to quantify right-to-
left shunt. Transcranial Doppler (TCD) is being done 
systematically at selected sites. To achieve the maximal 
accuracy in PFO diagnosis, the combined use of different 
techniques is warranted (10). However, as the majority 
of right-to-left shunts is represented by PFO, PFO-
related parameters are better evaluated by standardized 
step-by-step TEE compared with TTE. Further, whether 
3D echocardiography has incremental clinical and 
prognostic value over 2D echocardiography should be 
explored in future studies. Finally, TEE is a semi-invasive 
modality and its use in healthy volunteers is an ethical 
consideration. However, this is counter-balanced by the 
fact that complications related to TEE are rare. In a study 
population that included patients with a heart disease, 
the complication risk attributable to TEE was 0.2–0.5% 
(25). Complication risk of TEE is similar to that of 
gastroscopy and is usually associated with concomitant 
diseases of upper gastrointestinal tract. TEE will not be 
performed if any contraindication is found, including 
difficulty in swallowing, any upper gastrointestinal tract 
disease, severe cervical spinal arthrosis or a known risk of 
bleeding, coagulation abnormality or thrombocytopenia. 
Therefore, in healthy subjects without contraindications 
for the investigation or cardiac disease, the health risks 
associated with TEE are considered minimal. TEE may be 
therefore applied following individual agreement, and 
after approval by the local ethics committee.
Conclusion
Cardioembolic stroke is a syndromal disorder which 
includes multiple cardiac conditions, and may have 
devastating implications if occurred in early life. A detailed 
assessment of both conventional and unconventional 
vascular risk factors and cardiac imaging with TTE and TEE 
are implemented in SECRETO. Particularly, a standardized 
step-by-step TEE imaging aiming to the evaluation of both 
atria, LAA, Eustachian valve, Chiari network, interatrial 
septum aneurysm and defect and the anatomical shape 
and size of PFO, are implemented in the post-stroke 
screening work-up. The goal of SECRETO is to identify 
novel risk factors and cardiac imaging characteristics of 
cryptogenic stroke to advance current understanding, and 
ultimately enable more personalized therapeutic options 
for these patients.
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